LU76117A1 - - Google Patents

Info

Publication number
LU76117A1
LU76117A1 LU76117A LU76117A LU76117A1 LU 76117 A1 LU76117 A1 LU 76117A1 LU 76117 A LU76117 A LU 76117A LU 76117 A LU76117 A LU 76117A LU 76117 A1 LU76117 A1 LU 76117A1
Authority
LU
Luxembourg
Application number
LU76117A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9162099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU76117(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of LU76117A1 publication Critical patent/LU76117A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
LU76117A 1975-11-06 1976-11-03 LU76117A1 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7533899A FR2330383A1 (fr) 1975-11-06 1975-11-06 Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment

Publications (1)

Publication Number Publication Date
LU76117A1 true LU76117A1 (enExample) 1978-07-10

Family

ID=9162099

Family Applications (1)

Application Number Title Priority Date Filing Date
LU76117A LU76117A1 (enExample) 1975-11-06 1976-11-03

Country Status (24)

Country Link
US (2) US4252984A (enExample)
JP (1) JPS5848543B2 (enExample)
AR (1) AR214303A1 (enExample)
AT (1) AT344683B (enExample)
AU (1) AU501581B2 (enExample)
BE (1) BE847801A (enExample)
CA (1) CA1072981A (enExample)
CH (1) CH602582A5 (enExample)
DE (1) DE2649605C3 (enExample)
DK (1) DK145119C (enExample)
ES (1) ES452920A1 (enExample)
FI (1) FI62829C (enExample)
FR (1) FR2330383A1 (enExample)
GB (1) GB1515978A (enExample)
GR (1) GR61363B (enExample)
IE (1) IE43645B1 (enExample)
IL (1) IL50814A (enExample)
LU (1) LU76117A1 (enExample)
NL (1) NL179051C (enExample)
NO (1) NO142034C (enExample)
NZ (1) NZ182498A (enExample)
PT (1) PT65780B (enExample)
SE (1) SE433208B (enExample)
ZA (1) ZA766338B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2409980A1 (fr) * 1977-11-24 1979-06-22 Synthelabo Ethers de phenols et leur application en therapeutique
IT1147311B (it) * 1980-02-13 1986-11-19 Stabil Bioterapico Farmachim Eteri basici di 4-idrossi-benzofenoni con attivita' quali agenti betabloccanti e relativi procedimento di preparazione
ZW9881A1 (en) * 1980-06-02 1981-12-23 Hoffmann La Roche Substituted phenoxyaminopropanol derivatives
DE3125870C2 (de) * 1980-07-09 1994-09-15 William John Louis 3-Aminopropoxyphenyl Derivate, ihre Herstellung und sie enthaltende Arzneimittel
CH643527A5 (en) * 1980-10-24 1984-06-15 Ciba Geigy Ag Process for the preparation of 1-alkylamino-3-(4-(2-lower alkoxy-ethyl)phenoxy)-2-propanols
JPS57108047A (en) * 1980-11-06 1982-07-05 Sandoz Ag 3-aminopropoxyphenyl derivative, manufacture and pharmaceutical composition containing same
FI76551C (fi) 1980-11-06 1988-11-10 Sandoz Ag Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-aminopropoxifenylderivat.
US5347050A (en) * 1980-11-06 1994-09-13 Richard Berthold 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
DE3125636A1 (de) * 1981-06-30 1983-01-13 Merck Patent Gmbh, 6100 Darmstadt 1-(p-2-isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur senkung des augeninnendrucks und ophtalmikum, enthalten diese verbindung
FR2512443A1 (fr) * 1981-09-10 1983-03-11 Synthelabo Derives de phenoxy-3 propanol-2, leur preparation et leur application en therapeutique
DE3151201A1 (de) * 1981-12-23 1983-07-28 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkanolamine und phenoxyalkanol-cycloalkylamine, verfahren zu ihrer herstellung, diese verbindungen enthaltende pharmazeutische zubereitungen und zwischenprodukte
US4450172A (en) * 1982-03-10 1984-05-22 E. I. Du Pont De Nemours And Company Antihypertensive polyhalohydroxyisopropyl phenylalka(e)noic acid esters of alkylaminohydroxypropyloxyphenylalkyl alcohols
FR2536390B1 (fr) * 1982-11-22 1986-03-21 Synthelabo Isomere s du betaxolol, sa preparation et son application en therapeutique
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
US5166218A (en) * 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
NZ211815A (en) * 1984-05-15 1988-11-29 Warner Lambert Co Preparation of 1-((3,4-dimethoxyphenethyl)amino)-3- (3-tolyloxy)-2-propanol
GB8412864D0 (en) * 1984-05-19 1984-06-27 Smith Kline French Lab Chemical compounds
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
ES8609190A1 (es) * 1985-02-07 1986-07-16 Pharma Investi S A Un procedimiento para preparar eteres fenolicos
US5095151A (en) * 1985-05-21 1992-03-10 American Home Products Corporation Preparation of propranolol hydrochloride macrocrystals
EP0252007A3 (en) * 1986-06-28 1989-07-05 Ciba-Geigy Ag 2-propanol derivatives as corrosion inhibitors
US4694022A (en) * 1986-12-24 1987-09-15 Alcon Laboratories, Inc. Fatty acid salts of betaxolol useful in the treatment of glaucoma
DE3866984D1 (en) * 1987-07-21 1992-01-30 Hoffmann La Roche Phenoxypropanolamine.
FR2672594B1 (fr) * 1991-02-08 1994-07-01 Synthelabo Derives d'ethers de phenols, leur preparation et leur application en therapeutique.
EP0937030B1 (en) 1995-10-10 2004-03-31 William John Louis 3-amino-propoxyphenyl derivatives (i)
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
US5942633A (en) * 1996-06-19 1999-08-24 Abbott Laboratories Process for the selective alkylation of betaxolol intermediates
US5731463A (en) * 1996-09-23 1998-03-24 Abbott Laboratories Selective alkylation of an alcohol substituted phenol compound
EP1079859B1 (en) 1998-05-22 2010-07-14 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US6258350B1 (en) 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
PT1244438E (pt) 1999-11-30 2004-02-27 Alcon Inc Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externa
US20020123485A1 (en) * 2000-07-27 2002-09-05 Alexander John C. Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
GEP20074134B (en) 2002-08-19 2007-06-25 Pfizer Prod Inc Combination therapy for hyperproliferative diseases
NZ577031A (en) * 2003-05-30 2010-09-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-CO inhibitors
CN1300079C (zh) * 2004-12-03 2007-02-14 南京大学 合成4－[2－(环丙基甲氧基)乙基]苯酚的新工艺
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
CL2007002044A1 (es) * 2006-07-14 2008-06-13 Ranbaxy Lab Ltd Polimorfo cristalino de la sal hemicalcica del acido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxiheptanoico; composicion farmaceutica; y uso para el tratamiento de la diabetes, enf
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
CN101594878A (zh) 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
WO2008105442A1 (ja) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド誘導体
WO2008112287A1 (en) * 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-beta blocker conjugates
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
EP2050441A1 (en) * 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
JP2009040769A (ja) * 2008-07-09 2009-02-26 William John Louis ３−アミノ−プロポキシフェニル誘導体（ｉ）
NZ616673A (en) 2009-02-20 2014-08-29 To Bbb Holding B V Glutathione-based drug delivery system
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
DK3911648T3 (da) 2019-01-18 2025-01-13 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT326107B (de) * 1935-11-15 1975-11-25 Boehringer Sohn Ingelheim Verfahren zur herstellung von neuen racemischen oder optisch aktiven n,n'-bis- (3-subst. phenoxy-2-hydroxy-1-propyl) -alpha,omega- diaminoalkanen sowie deren säureadditionssalzen
GB1078852A (en) * 1964-09-30 1967-08-09 Ici Ltd Alkanolamine derivatives
CA956632A (en) * 1969-05-16 1974-10-22 Yoshitomi Pharmaceutical Industries Phenoxy-aminopropanol derivatives
SE372762B (enExample) * 1969-05-21 1975-01-13 Haessle Ab
US3712890A (en) * 1969-06-20 1973-01-23 Ici Ltd Process for making 2-aryloxymethyl morpholines
SE354851B (enExample) * 1970-02-18 1973-03-26 Haessle Ab
GB1458392A (en) * 1973-11-09 1976-12-15 Ici Ltd Optically-active 1-aryloxy-2,3-epoxypropane derivatives

Also Published As

Publication number Publication date
BE847801A (fr) 1977-02-14
DK495476A (da) 1977-05-07
GB1515978A (en) 1978-06-28
IE43645L (en) 1977-05-06
PT65780A (fr) 1976-12-01
PT65780B (fr) 1978-05-10
DE2649605A1 (de) 1977-05-18
GR61363B (en) 1978-10-30
FI62829B (fi) 1982-11-30
FI763132A7 (enExample) 1977-05-07
NL7612123A (nl) 1977-05-10
DE2649605B2 (de) 1980-07-10
JPS5285146A (en) 1977-07-15
SE433208B (sv) 1984-05-14
ZA766338B (en) 1977-10-26
AU501581B2 (en) 1979-06-21
AU1925976A (en) 1978-05-11
NL179051B (nl) 1986-02-03
IL50814A (en) 1979-11-30
DE2649605C3 (de) 1981-04-02
DK145119C (da) 1983-02-14
NL179051C (nl) 1986-07-01
US4311708A (en) 1982-01-19
FR2330383A1 (fr) 1977-06-03
AR214303A1 (es) 1979-05-31
AT344683B (de) 1978-08-10
IE43645B1 (en) 1981-04-22
CA1072981A (en) 1980-03-04
NO142034C (no) 1980-06-18
FR2330383B1 (enExample) 1979-09-21
CH602582A5 (enExample) 1978-07-31
NZ182498A (en) 1978-04-03
US4252984A (en) 1981-02-24
IL50814A0 (en) 1977-01-31
ATA812076A (de) 1977-12-15
ES452920A1 (es) 1977-11-01
NO142034B (no) 1980-03-10
DK145119B (da) 1982-09-06
SE7612177L (sv) 1977-05-07
NO763732L (no) 1977-05-09
JPS5848543B2 (ja) 1983-10-28
FI62829C (fi) 1983-03-10

Similar Documents

Publication Publication Date Title
FR2330383B1 (enExample)
CH600971A5 (enExample)
CH607253A5 (enExample)
BG21550A1 (enExample)
BG21559A1 (enExample)
BG21571A1 (enExample)
BG22120A1 (enExample)
BG22179A1 (enExample)
BG22357A1 (enExample)
BG22691A1 (enExample)
BG22896A1 (enExample)
BG23360A1 (enExample)
CH1169075A4 (enExample)
CH1617075A4 (enExample)
CH1667475A4 (enExample)
CH579725A5 (enExample)
CH579782A5 (enExample)
CH580802A5 (enExample)
CH585623A5 (enExample)
CH586698A5 (enExample)
CH590552A5 (enExample)
CH591668A5 (enExample)
CH594135A5 (enExample)
CH594882A5 (enExample)
CH596178A5 (enExample)